Cumberland Pharmaceuticals Inc. (CPIX) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-102.6%

-$0.11

vs $4.22 price

Levered DCF

$11.56

After debt service

Piotroski score

3 / 9

Weak

Altman Z-score

0.04

Distress zone

Rating

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	-20.95×	-5.15×	-4.07×	-5.92×	-19.46×	-13.41×	-22.39×	-13.4×
P/B	2.39×	1.46×	0.86×	0.9×	1.63×	0.95×	1.55×	1.68×
P/S	1.34×	0.88×	0.65×	0.78×	1.93×	1.19×	2.31×	2.3×
EV / EBITDA	19.7×	196.97×	167.64×	102.03×	-68.34×	-25.19×	-15.64×	-10.5×
Gross margin	85.0%	82.6%	84.7%	78.3%	75.5%	76.9%	78.4%	81.9%
Operating margin	-6.3%	-17.0%	-24.2%	-13.6%	-21.3%	-17.0%	-27.0%	-18.1%
Net margin	-6.4%	-17.1%	-15.9%	-13.3%	-9.7%	-8.9%	-10.3%	-17.1%
Current ratio	1.01×	1.15×	1.28×	1.6×	2.37×	1.95×	2.08×	2.69×
Debt / equity	0.41×	0.9×	0.62×	0.58×	0.38×	0.41×	0.42×	0.36×
Interest coverage	-5.63×	-10.62×	-14.31×	-9.74×	-78.32×	-24.21×	-37.73×	-37.74×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	-11.4%	-28.4%	-21.2%	-15.4%	-8.2%	-7.1%	-6.9%	-12.5%
Return on invested capital	-6.9%	-13.0%	-17.6%	-8.8%	-11.6%	-8.6%	-11.3%	-8.7%
Return on assets	-3.7%	-8.6%	-7.7%	-6.0%	-4.2%	-3.5%	-3.4%	-6.2%
Free cash flow yield	8.1%	-2.4%	22.0%	19.5%	8.6%	7.4%	3.5%	-1.2%
Earnings yield	-4.8%	-19.4%	-24.5%	-17.0%	-5.0%	-7.5%	-4.5%	-7.4%
Enterprise value	$58.3M	$35.9M	$25.7M	$34M	$58.6M	$39.2M	$72.6M	$86M
Net debt / EBITDA	-0.43×	14.3×	0.7×	3.61×	12.8×	3.52×	1.45×	0.97×
Cash conversion cycle (days)	-537	-437	-477	76	20	4	28	898